<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174368</url>
  </required_header>
  <id_info>
    <org_study_id>1003010955</org_study_id>
    <nct_id>NCT01174368</nct_id>
  </id_info>
  <brief_title>Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T</brief_title>
  <official_title>An Open-Label, Phase II Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of
      subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel,
      cabazitaxel) and evidence of disease progression on androgen-axis inhibition and/or
      immunotherapy in the form of sipuleucel-T.

      The treatment is being evaluated for its effect on tumor growth. It consists of the placement
      (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA
      macrobeads). The cells in the macrobeads produce substances that have been shown to slow or
      stop the growth of tumors in experimental animals and veterinary patients. It has been tested
      in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II
      studies in patients with colorectal, pancreatic or prostate cancers are in progress.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2010</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>16 months</time_frame>
    <description>Data was not collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Metastases</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>16 months</time_frame>
    <description>No data was collected.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer macrobeads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer Macrobead placement in abdominal cavity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cancer Macrobead placement in abdominal cavity</intervention_name>
    <description>8 macrobeads per kilogram</description>
    <arm_group_label>Cancer macrobeads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer of prostate

          -  Evidence of metastasis

          -  Failed available therapies

          -  Resolution of any toxic effects of previous therapies

          -  Performance status (ECOG PS) 0-2

          -  Adequate hematologic, coagulation (INR 2-3max), hepatic and renal function

          -  Life expectancy of 12 months

          -  Agrees to contraceptive use while on study if sexually active

          -  Sign informed consent document

        Exclusion Criteria:

          -  Any condition presenting an unacceptably high anesthetic or surgical risk

          -  HIV positive

          -  Cognitive impairment such as to preclude informed consent

          -  Other surgical treatment, chemotherapy and radiation within four weeks of baseline

          -  Inadequate hematologic, coagulation (INR &gt;3), hepatic, renal function

          -  Hepatic blood flow abnormalities and/or large-volume ascites

          -  Concurrent cancer of any other type except skin cancer (excluding melanoma)

          -  History of allergic reactions to mouse antigens

          -  Active infection, congestive heart failure, unstable angina, serious cardiac
             arrhythmias, psychiatric illness, difficult social situations not permitting reliable
             participation, active bleeding
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry H Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 1, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <results_first_submitted>May 29, 2018</results_first_submitted>
  <results_first_submitted_qc>October 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2018</results_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cancer Macrobeads</title>
          <description>Cancer Macrobead placement in abdominal cavity
Cancer Macrobead placement in abdominal cavity: 8 macrobeads per kilogram</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No analysis was performed due to small sample size. The one baseline participant withdrew voluntarily from the study after first implantation.</population>
      <group_list>
        <group group_id="B1">
          <title>Cancer Macrobeads</title>
          <description>Cancer Macrobead placement in abdominal cavity
Cancer Macrobead placement in abdominal cavity: 8 macrobeads per kilogram</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Data was not collected.</description>
        <time_frame>16 months</time_frame>
        <population>Data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cancer Macrobeads</title>
            <description>Cancer Macrobead placement in abdominal cavity
Cancer Macrobead placement in abdominal cavity: 8 macrobeads per kilogram</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Data was not collected.</description>
          <population>Data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Metastases</title>
        <time_frame>16 months</time_frame>
        <population>Data was not collected. No statistical analysis was performed due to the sample size of one patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Cancer Macrobeads</title>
            <description>Cancer Macrobead placement in abdominal cavity
Cancer Macrobead placement in abdominal cavity: 8 macrobeads per kilogram</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Metastases</title>
          <population>Data was not collected. No statistical analysis was performed due to the sample size of one patient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>No data was collected.</description>
        <time_frame>16 months</time_frame>
        <population>Data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cancer Macrobeads</title>
            <description>Cancer Macrobead placement in abdominal cavity
Cancer Macrobead placement in abdominal cavity: 8 macrobeads per kilogram</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>No data was collected.</description>
          <population>Data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cancer Macrobeads</title>
          <description>Cancer Macrobead placement in abdominal cavity
Cancer Macrobead placement in abdominal cavity: 8 macrobeads per kilogram</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angelica Nazarian</name_or_title>
      <organization>The Rogosin Institute</organization>
      <phone>212-746-1551</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

